As European markets grapple with the fallout from higher-than-expected U.S. trade tariffs, which have led to significant declines in major indices like the STOXX Europe 600 and Germany's DAX, investors are keenly observing how these developments might impact high-growth tech stocks in the region. In such volatile conditions, a good stock is often characterized by its ability to demonstrate resilience through innovation and adaptability while maintaining strong fundamentals amidst broader economic uncertainties.

Top 10 High Growth Tech Companies In Europe

Name Revenue Growth Earnings Growth Growth Rating Pharma Mar 24.24% 40.82% ★★★★★★ Yubico 20.94% 26.69% ★★★★★★ Truecaller 20.10% 24.70% ★★★★★★ Elicera Therapeutics 63.53% 97.24% ★★★★★★ Devyser Diagnostics 26.28% 96.52% ★★★★★★ Skolon 29.73% 91.18% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ CD Projekt 33.78% 37.39% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★

Click here to see the full list of 237 stocks from our European High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Crayon Group Holding

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Crayon Group Holding ASA is an IT consultancy company that operates through its subsidiaries, with a market capitalization of NOK9.38 billion.

Operations: Crayon Group generates revenue primarily from Services and Software & Cloud segments, with Consulting services contributing NOK2.87 billion and Software & Cloud Direct adding NOK2.29 billion. The company's focus on these areas highlights its role in IT consultancy and software solutions, leveraging expertise to drive growth in cloud economics and direct software sales.

Crayon Group Holding has demonstrated a robust turnaround, transitioning from a net loss to reporting a net income of NOK 43 million in the latest quarter, underscoring its recovery and operational improvements. With annual revenue growth projected at 12.2%, Crayon is outpacing the Norwegian market's average but still trails behind the high-growth benchmarks typically seen in tech sectors. However, its earnings growth forecast at an impressive 35.8% annually significantly exceeds local market expectations. This financial rejuvenation is complemented by strategic R&D investments aimed at fostering innovation and maintaining competitive edge in software solutions, positioning Crayon for potential sustained growth amidst evolving technological landscapes.

Click here and access our complete health analysis report to understand the dynamics of Crayon Group Holding. Gain insights into Crayon Group Holding's historical performance by reviewing our past performance report.

Story Continues

OB:CRAYN Earnings and Revenue Growth as at Apr 2025

BioArctic

Simply Wall St Growth Rating: ★★★★★★

Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK15.09 billion.

Operations: The company generates revenue primarily through its biotechnology segment, amounting to SEK 257.35 million.

BioArctic's recent presentations at the 2025 International Conference on Alzheimer's and Parkinson's Diseases underscore its innovative strides in neurodegenerative disease treatment. Highlighting their R&D prowess, the company showcased promising data on exidavnemab and lecanemab, which are pivotal to their strategy in targeting complex neurological disorders. These developments not only reflect BioArctic’s commitment to advancing healthcare but also align with industry trends towards targeted biologic therapies. The collaboration with Eisai and recent regulatory nods further bolster their market position, potentially accelerating revenue growth which is forecasted at a robust 31% annually.

Dive into the specifics of BioArctic here with our thorough health report. Understand BioArctic's track record by examining our Past report.OM:BIOA B Earnings and Revenue Growth as at Apr 2025

Hemnet Group

Simply Wall St Growth Rating: ★★★★★☆

Overview: Hemnet Group AB (publ) operates a residential property platform in Sweden with a market capitalization of approximately SEK33.93 billion.

Operations: The company generates revenue primarily through its Internet Information Providers segment, amounting to SEK1.39 billion.

Hemnet Group has demonstrated robust financial performance, with a notable increase in annual revenue to SEK 1.4 billion, up from SEK 1 billion the previous year, and a surge in net income to SEK 481.4 million from SEK 338.7 million. These figures underscore a significant earnings growth of 42.1% over the past year, outpacing the industry average of 10.9%. Additionally, Hemnet's strategic share repurchases totaling SEK 264.2 million reflect its confidence in sustaining growth momentum amidst competitive pressures in the Interactive Media and Services sector.

Navigate through the intricacies of Hemnet Group with our comprehensive health report here. Explore historical data to track Hemnet Group's performance over time in our Past section.OM:HEM Revenue and Expenses Breakdown as at Apr 2025

Make It Happen

Dive into all 237 of the European High Growth Tech and AI Stocks we have identified here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Contemplating Other Strategies?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OB:CRAYN OM:BIOA B and OM:HEM.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments